ASH 2025: Cell Therapy Post-Conference Report

What’s Inside the Report?

Navigate the most impactful cell therapy developments showcased at ASH 2025, carefully captured in a single, easy-to-navigate report:

• 248 cell therapy-relevant abstracts analyzed, including 196 clinical, 16 trial outlines, and 38 preclinical studies, an increase of 25% from ASH 2024.
• 12 newly identified assets tracked across a range of trial phases, with 40% of clinical trials in Phase 1, indicating early-stage innovation.
• Detailed trial phase and therapeutic class breakdowns, spotlighting the rise of allogeneic, off-the-shelf, and logic-gated CAR and NK cell therapies.
• In vivo CAR spotlight featuring 9 assets (8 preclinical, 1 clinical), with new targets such as BCMA and delivery systems like LNP and viral vectors.
• Top targets analyzed, including CD19 and BCMA, which together account for 64.1% of all assets, plus emerging tri-targeted constructs.
• Clinical highlights from key trials with response rates, safety profiles, and regulatory designations, enabling direct benchmarking of competitors and pipeline strategy.

Whether you’re tracking competitive movement, evaluating scientific trajectories, informing BD and CI planning, or simply staying current with the meeting’s most relevant findings, this report distills ASH’s complex data into the insights that matter most – without the time-intensive review of every abstract.